María Victoria
Mateos Manteca
Profesora Titular de Universidad
![Foto de María Victoria](/img/nophoto.png)
![Foto de University of Alberta](/img/noimage_org.png)
University of Alberta
Edmonton, CanadáPublications en collaboration avec des chercheurs de University of Alberta (12)
2022
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414
2021
-
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
British Journal of Haematology
-
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718
-
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Journal of Hematology and Oncology
-
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130
2020
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2017
-
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905
-
Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
Haematologica, Vol. 102, Núm. 10, pp. 1767-1775
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
-
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report
Blood, Vol. 125, Núm. 13, pp. 2068-2074